Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
33.71
+0.04 (0.12%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $168.33M in the quarter ending June 30, 2024, with 24.17% growth. This brings the company's revenue in the last twelve months to $630.16M, down -0.61% year-over-year. In the year 2023, Supernus Pharmaceuticals had annual revenue of $607.52M, down -8.95%.
Revenue (ttm)
$630.16M
Revenue Growth
-0.61%
P/S Ratio
2.93
Revenue / Employee
$966,508
Employees
652
Market Cap
1.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
Dec 31, 2019 | 392.76M | -16.14M | -3.95% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Patterson Companies | 6.53B |
National HealthCare | 1.17B |
Omnicell | 1.08B |
10x Genomics | 631.73M |
Mirum Pharmaceuticals | 264.38M |
MannKind | 248.37M |
Recursion Pharmaceuticals | 49.64M |
Celldex Therapeutics | 8.30M |
SUPN News
- 1 day ago - Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - GlobeNewsWire
- 5 days ago - Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - GlobeNewsWire
- 12 days ago - Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - GlobeNewsWire
- 4 weeks ago - Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree - GlobeNewsWire
- 4 weeks ago - Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - GlobeNewsWire
- 5 weeks ago - Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives - Seeking Alpha
- 5 weeks ago - ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug - Benzinga
- 7 weeks ago - Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference - GlobeNewsWire